FDA-cleared ChloraDerm is now available in a new design with a reinforced border, suited for advanced IV catheter securement, according to San Francisco-based entrotech life sciences.
ChloraDerm is a transparent film dressing containing the Chlorhexidine Advantage, a colophony-and acid-free, edge-to-edge chlorhexidine matrix with effectiveness against multi-drug-resistant organisms, including MRSA for at least seven days.
The new design integrates a soft cloth reinforced border into the ChloraDerm dressing platform providing healthcare providers with added comfort and securement feature for IV catheter sites when more robust dressing security and stability are required for the patient.
The dressing is used to cover and secure primary dressings and protect wounds with percutaneous medical devices that could result in a central line associated bloodstream infection. ChloraDerm achieves reduction against yeasts and gram positive and negative bacteria, including multiple drug-resistant organisms (MRSA, MRSE, VRE, MDR).
Compared to common non-antimicrobial dressings,the product demonstrates greater effectiveness against these organisms at one, three and seven days, without adding increased cost or complexity, according to the company. Central line associated bloodstream infections afflict nearly 100,000 people per year and can cause severe harm or death.
The 2011 CDC Guidelines for the Prevention of Intravascular Catheter-Related Infections recommend Chlorhexidine impregnated dressings be considered for central venous catheter central line associated bloodstream infection prevention.
